Researchers from the University of Manchester in the UK have developed a new nanoscale blood test technique for obtaining more information using blood collected from cancer patients.
The latest discovery could potentially speed up early diagnosis, drug discovery and lead to advancements in personalized medicines.
The University of Scientists from Women with Advanced Ovarian Cancer, CAELYX, is a type of chemotherapy group called CAELYX.
"The nanoscale blood test can potentially speed up early diagnosis, drug discovery and lead to advancements in personalized medicines."
The drug is contained in soft, lipid-based nanoparticles, called liposome that helps reduce the effects of chemotherapy by acting as a vessel.
As part of the study, which has been funded by Cancer Research UK, scientists were able to detect different biomolecules that were stuck on the surface of the liposome, called the 'Corona biomolecule'.
University of Manchester lead author professor Kostas Costaelos said: "We hope that this technique can be used for further research, from monitoring progression to recurrence to finding a new biomarkers for early diagnosis."
The discovery will also help develop a better technique to gather information from the blood of patients.
University of Manchester study author Dr. Marilena Hadjidemetriou said: "The blood is a potential gold of information, but there is a challenge to the signal that would otherwise be buried within the 'noise'."
Cancer Research UK liquid biopsies expert professor Caroline Dive said: "Liquid biopsies are quicker, less invasive than many other tests, and this is an important early step in developing such a test."
There are plans for using the best method to help find the best biomarkers for early stages of the disease.